The KMT2A gene helps control when other genes turn on and off, especially during early development and blood cell formation. This gene plays an important role in growth, learning, and the making of healthy blood cells. If this gene does not work properly from birth, it can cause a condition that affects development and growth. Acquired broken-and-rejoined forms of the KMT2A gene in blood cells are also a well-known cause of some leukemias.
What is a gene?
Genes are stretches of DNA that carry instructions your cells use to make molecules or regulate activities in the body. Some genes provide the information needed to make proteins, the parts of cells that do the work. Others mainly guide when certain processes happen, where they take place, and how strongly they are carried out. Together, genes affect how the body develops and functions, and they can also influence how you respond to food, stress, or medications. For a deeper look at this topic, you can find more in the LearnHub.
Overview
KMT2AGene function
What if the gene works
The KMT2A gene helps turn other genes on and off at the right time. This supports early development, normal growth, and the formation of blood cells.
Risk
What if the gene does not work
Depending on the variant, changes in the KMT2A gene can cause Wiedemann-Steiner syndrome, with developmental, growth, and facial features that range from mild to more marked, or they can drive certain leukemias when the gene becomes rearranged in blood cells.
Treatment
What does that mean for your treatment
In acute leukemia with a rearrangement involving the KMT2A gene, treatment may include a menin inhibitor such as revumenib, mainly when earlier treatment has not worked well enough. This finding can also shape risk-based treatment planning. For inherited conditions caused by a pathogenic variant in the KMT2A gene, no KMT2A-specific drug treatment is established.
Conditions associated with KMT2A
Gene function
What if the gene works
Your cells use the KMT2A gene to keep important growth and identity instructions available at the right time. It helps manage which genes are active, especially during early development and as cells mature into their usual roles. Understanding what the KMT2A gene does helps explain how tissues grow in an organized, stable way.
KMT2A helps switch on selected genes when cells need them. This gives cells access to the right instructions for growth, renewal, and day to day work.
Its protein places small chemical tags on DNA packaging proteins called histones. These tags help keep active parts of the genetic code open and easier for the cell to read.
KMT2A helps cells hold on to their job specific program as they mature. This is especially important in blood forming cells, which need stable instructions as they develop and renew.
During early growth, KMT2A helps control groups of genes that guide body patterning and tissue formation. This supports the orderly timing of developmental steps across many tissues.
What is a variant?
A genetic variant is a minor difference in the DNA sequence within a gene. These differences are common and help shape normal human diversity, including variation in appearance, metabolism, and how the body responds to environmental influences. Many variants do not have any noticeable effect and simply represent natural genetic variation. In some cases, though, a variant can change how a gene functions more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the KMT2A gene often reduce how well a cell can make or use the KMT2A protein, which can disrupt control of other genes during early development. The effects of KMT2A gene variants range from milder changes that partly lower protein activity to more severe variants that shorten the protein or stop it from being made. In people with pathogenic variants, this difference can influence how early features of Wiedemann-Steiner syndrome appear and how strongly they affect growth, learning, and development.
How variants are linked to conditions
Pathogenic variants in the KMT2A gene cause Wiedemann-Steiner syndrome, a condition linked with developmental delay, short stature, low muscle tone, and recognizable facial features. Inherited KMT2A gene variants are linked to Wiedemann-Steiner syndrome far more clearly than to any other inherited condition. Separate acquired changes involving the KMT2A gene are also found in some blood cancers, especially certain leukemias, but these changes usually develop during life rather than being passed down in families.
A variant is not necessarily a diagnosis
Genetic variants are a usual part of human biology and are common across the general population. Most have no direct impact on health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when multiple genes and environmental factors also play a role. In some situations, though, a single well characterized variant in a specific gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For KMT2A, risk is mainly shaped by genetics, not lifestyle. A child’s chance is higher if a parent carries a disease-causing KMT2A change, while many cases happen for the first time in the child; there is not enough evidence to say diet, exercise, or other everyday factors lower this risk.
Inheritance of KMT2A variants
KMT2A-related conditions are usually inherited in an autosomal dominant pattern, which means one altered copy of the KMT2A gene can be enough to cause the condition. If a parent carries a disease-causing KMT2A variant in their germline, each child has a 50% chance of inheriting it. Many people diagnosed with a KMT2A-related condition have a new, de novo variant that was not inherited from either parent. In families asking how KMT2A variants are inherited, both inherited and de novo cases are well recognized.
What does my KMT2A result mean for my family?
For inherited KMT2A-related conditions such as Wiedemann-Steiner syndrome, the pattern is usually dominant, so close relatives like parents, brothers, sisters, and children may also carry the same gene change. In many families, though, the change starts new in the affected person and is not found in either parent. The meaning for relatives depends on whether the result is an inherited change present in the body’s cells or a change found only in cancer cells.
Genetic information
Genetic testing
How you find out about variants
Testing for changes in the KMT2A gene usually uses a blood sample, saliva, or a cheek swab. KMT2A genetic testing reads the DNA code to look for variants, including small spelling changes and larger missing or extra pieces, and the result may help show whether a variant is present and whether it appears inherited or new.
When should I consider getting a genetic test?
Genetic testing for the KMT2A gene may be considered when a child has unexplained developmental delay, learning problems, short stature, or unusually thick hair growth along with other features that suggest Wiedemann-Steiner syndrome. It can also be helpful when there is a family history of this condition or a known KMT2A change in the family.
A genetic result is only one part of your health story
A genetic finding can provide useful insight, but how much it explains varies by the condition and the type of variant involved. Many other factors, including lifestyle, environment, age, and medical history, also shape how the body works over time. For some conditions, especially those influenced by many genes, genetic information provides context rather than certainty and is most useful when considered alongside other parts of care. In other situations, a genetic result can offer a clear answer. In areas such as medication response, these results can help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small differences in genes can change how the body breaks down a drug, moves it through the body, or responds at the drug’s target. This is common and helps explain why the same treatment works well for one person, works less well for another, or causes more side effects in someone else. Genetic information is one factor among many, alongside age, kidney and liver function, other medicines, and overall health.
What is Pharmacogenetics?
Pharmacogenetics examines how genetic differences shape a person’s response to medications. By looking at links between genes and drugs, it helps explain why the same treatment may work differently from one person to another. For many medicines, genes influence both how strongly a drug works and how the body handles it. This information can support treatment decisions that are more informed and more individualized. More detail on this topic is available in the LearnHub.
Drugs influenced by the KMT2A gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding routine medication response, so any questions about medicines, side effects, or changes in health are best discussed with your doctor.
History
The KMT2A gene has an important place in cancer genetics because it was first brought to attention through certain leukemias with recurring chromosome changes. In the 1990s, researchers identified this gene at chromosome 11q23 and named it MLL, short for mixed lineage leukemia, after its link to leukemias that showed features of more than one blood cell type. Scientific classifications changed as researchers learned more about the gene. Over time, the name shifted from MLL to the KMT2A gene to better reflect its broader biological role and to use clearer, more standardized naming. These discoveries helped explain why some infant and treatment-related leukemias behave differently, and they made the KMT2A gene a major focus of blood cancer research.